AORT Stock Analysis: Artivion | NYSE

Medical Devices | NYSE, USA | Market Cap: 1.189m USD | 12M Return: -26% | Charts, Fundamentals & Technical Analysis

Heart Valves, Stent Grafts, Surgical Sealants, Vascular Grafts
Total Rating 32
Safety 80
Buy Signal -0.96
Medical Devices
Industry Rotation: +0.0
Market Cap: 1.19B
Avg Turnover: 18.4M
Risk 3d forecast
Volatility66.5%
VaR 5th Pctl10.8%
VaR vs Median-1.31%
Reward TTM
Sharpe Ratio-0.38
Rel. Str. IBD1.7
Rel. Str. Peer Group2.9
Character TTM
Beta0.870
Beta Downside1.003
Hurst Exponent0.506
Drawdowns 3y
Max DD57.80%
CAGR/Max DD0.27
CAGR/Mean DD1.38
EPS (Earnings per Share) EPS (Earnings per Share) of AORT over the last years for every Quarter: "2021-06": 0.12, "2021-09": -0.05, "2021-12": -0.51, "2022-03": 0.03, "2022-06": -0.03, "2022-09": -0.05, "2022-12": 0.05, "2023-03": -0.33, "2023-06": -0.07, "2023-09": -0.24, "2023-12": -0.1, "2024-03": 0.06, "2024-06": -0.05, "2024-09": -0.05, "2024-12": -0.3936, "2025-03": -0.012, "2025-06": 0.24, "2025-09": 0.16, "2025-12": 0.17, "2026-03": 0.08,
Last SUE: 0.20
Qual. Beats: 0
Revenue Revenue of AORT over the last years for every Quarter: 2021-06: 76.148, 2021-09: 72.207, 2021-12: 79.394, 2022-03: 77.213, 2022-06: 80.34, 2022-09: 76.838, 2022-12: 79.398, 2023-03: 83.229, 2023-06: 89.251, 2023-09: 87.854, 2023-12: 93.67, 2024-03: 97.431, 2024-06: 98.019, 2024-09: 95.779, 2024-12: 97.308, 2025-03: 98.978, 2025-06: 112.972, 2025-09: 113.388, 2025-12: 115.992, 2026-03: 116.337,
Rev. CAGR: 11.60%
Rev. Trend: 98.6%
Last SUE: 0.19
Qual. Beats: 0

Warnings

P/E Ratio 98.0
Strong Share Dilution
Below Sma 200d

Tailwinds

No distinct edge detected

Seasonality 10.5 years of data

Jan -3.3% 16
Feb +0.3% 2
Mar -0.9% 0
Apr +4.7% 10
May +0.5% 16
Jun +3.4% 34
Jul -0.0% 5
Aug +2.6% 6
Sep -5.0% 38
Oct -14.6% 68
Nov +8.6% 39
Dec -1.8% 22

How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.

Description: AORT Artivion

Artivion, Inc. is a U.S.-based medical device company that manufactures, processes, and distributes implantable medical devices and human tissues for cardiac and vascular surgery customers worldwide. The company operates within the Health Care Equipment sub-industry, addressing niches in heart valve replacement, aortic disease treatment, and surgical sealing and tissue preservation.

Its product portfolio spans mechanical and tissue heart valves (including the On-X line and CryoValve SG pulmonary valve), a broad family of stent graft systems for aortic and peripheral vascular procedures (E-vita, E-nside, E-tegra, NEXUS, and others), surgical sealants (BioGlue), and decellularized tissue and patch products (SynerGraft, PhotoFix). The business is typically categorized as a specialty medical device and tissue-engineering company, combining capital-implant sales with recurring tissue-preservation services.

Artivion sells primarily through a direct sales force targeting physicians, hospitals, and other healthcare facilities. The company was incorporated in 1984 as CryoLife, Inc., is headquartered in Kennesaw, Georgia, and adopted its current name in January 2022.

Headlines to Watch Out For
  • AMDS and NEXUS stent graft systems drive aortic segment revenue growth
  • On-X heart valve and BioGlue sealant sales anchor recurring device revenue
  • FDA and CE Mark approvals accelerate new aortic repair product launches
Piotroski VR-10 (Strict) 2.5
Net Income: 11.7m TTM > 0 and > 6% of Revenue
FCF/TA: 0.01 > 0.02 and ΔFCF/TA 1.51 > 1.0
NWC/Revenue: 46.09% < 20% (prev 60.33%; Δ -14.25% < -1%)
CFO/TA 0.06 > 3% & CFO 56.2m > Net Income 11.7m
Net Debt (245.2m) to EBITDA (65.1m): 3.77 < 3
Current Ratio: 3.28 > 1.5 & < 3
Outstanding Shares: last quarter (49.7m) vs 12m ago 17.76% < -2%
Gross Margin: 62.94% > 18% (prev 63.94%; Δ -1.00% > 0.5%)
Asset Turnover: 54.79% > 50% (prev 49.31%; Δ 5.49% > 0%)
Interest Coverage Ratio: 1.72 > 6 (EBIT TTM 41.7m / Interest Expense TTM 24.3m)
Altman Z'' 2.81
A: 0.24 (Total Current Assets 304.1m - Total Current Liabilities 92.7m) / Total Assets 883.2m
B: -0.06 (Retained Earnings -50.1m / Total Assets 883.2m)
C: 0.05 (EBIT TTM 41.7m / Avg Total Assets 837.2m)
D: 1.04 (Book Value of Equity 450.5m / Total Liabilities 432.7m)
Altman-Z'' = 2.81 = A
Beneish M -2.94
DSRI: 0.94 (Receivables 105.6m/95.8m, Revenue 458.7m/390.1m)
GMI: 1.02 (GM 63.94% / 62.94%)
AQI: 1.00 (AQ_t 0.54 / AQ_t-1 0.54)
SGI: 1.18 (Revenue 458.7m / 390.1m)
TATA: -0.05 (NI 11.7m - CFO 56.2m) / TA 883.2m)
Beneish M = -2.94 (Cap -4..+1) = A
What is the price of AORT shares?

As of July 11, 2026, the stock is trading at USD 24.09 with a total of 225,206 shares traded. Over the past week, the price has changed by +0.50%, over one month by +17.68%, over three months by -35.98% and over the past year by -26.01%.

Current recommended Stop Loss: 20.80 (which is 13.7% or 2.7 ATR below the current price).

Is AORT a buy, sell or hold?

Artivion has received a consensus analysts rating of 4.67. Therefore, it is recommended to buy AORT.

  • StrongBuy: 4
  • Buy: 2
  • Hold: 0
  • Sell: 0
  • StrongSell: 0

What are the forecasts/targets for the AORT price?
Analysts Target Price 42 74.3%
Artivion (AORT) - Fundamental Data Overview as of 08 July 2026
Market Cap USD = 1.19b (1.19b USD * 1.0 USD.USD)
P/E Trailing = 98.0
P/E Forward = 149.2537
P/S = 2.5929
P/B = 2.5831
P/EG = 643.75
Revenue TTM = 458.7m USD
EBIT TTM = 41.7m USD
EBITDA TTM = 65.1m USD
Long Term Debt = 215.4m USD (from longTermDebt, last quarter)
Short Term Debt = 5.53m USD (from shortTermDebt, last quarter)
Debt = 301.0m USD (from shortLongTermDebtTotal, last quarter) + Leases 42.8m
Net Debt = 245.2m USD (calculated: Debt 301.0m - CCE 55.8m)
Enterprise Value = 1.43b USD (1.19b + Debt 301.0m - CCE 55.8m)
Interest Coverage Ratio = 1.72 (Ebit TTM 41.7m / Interest Expense TTM 24.3m)
EV/FCF = 111.8x (Enterprise Value 1.43b / FCF TTM 12.8m)
FCF Yield = 0.89% (FCF TTM 12.8m / Enterprise Value 1.43b)
FCF Margin = 2.80% (FCF TTM 12.8m / Revenue TTM 458.7m)
Net Margin = 2.55% (Net Income TTM 11.7m / Revenue TTM 458.7m)
Gross Margin = 62.94% ((Revenue TTM 458.7m - Cost of Revenue TTM 170.0m) / Revenue TTM)
Gross Margin QoQ = 61.49% (prev 60.06%)
Tobins Q-Ratio = 1.62 (Enterprise Value 1.43b / Total Assets 883.2m)
Interest Expense / Debt = 8.07% (Interest Expense 24.3m / Debt 301.0m)
Taxrate = 32.87% (5.72m / 17.4m)
NOPAT = 28.0m (EBIT 41.7m * (1 - 32.87%))
Current Ratio = 3.28 (Total Current Assets 304.1m / Total Current Liabilities 92.7m)
Debt / Equity = 0.67 (Debt 301.0m / totalStockholderEquity, last quarter 450.5m)
Debt / EBITDA = 3.77 (Net Debt 245.2m / EBITDA 65.1m)
Debt / FCF = 19.11 (Net Debt 245.2m / FCF TTM 12.8m)
Total Stockholder Equity = 439.3m (last 4 quarters mean from totalStockholderEquity)
RoA = 1.40% (Net Income 11.7m / Total Assets 883.2m)
RoE = 2.66% (Net Income TTM 11.7m / Total Stockholder Equity 439.3m)
RoCE = 6.37% (EBIT 41.7m / Capital Employed (Equity 439.3m + L.T.Debt 215.4m))
RoIC = 3.62% (NOPAT 28.0m / Invested Capital 773.1m)
WACC = 8.31% (E(1.19b)/V(1.49b) * Re(9.04%) + D(301.0m)/V(1.49b) * Rd(8.07%) * (1-Tc(0.33)))
Discount Rate = 9.04% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 77.78 | Cagr: 9.08%
[DCF] Terminal Value 75.44% ; FCFF base≈12.8m ; Y1≈12.9m ; Y5≈13.6m
 [DCF] Fair Price = N/A (negative equity: EV 212.3m - Net Debt 245.2m = -32.9m; debt exceeds intrinsic value)
 EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.20 | # QB: 0
Revenue Correlation: 98.60 | Revenue CAGR: 11.60% | SUE: 0.19 | # QB: 0
EPS current Quarter (2026-06-30): EPS=0.10 | Chg30d=-12.09% | Revisions=-40% | Analysts=6
EPS next Quarter (2026-09-30): EPS=0.10 | Chg30d=-14.03% | Revisions=-40% | Analysts=6
EPS current Year (2026-12-31): EPS=0.44 | Chg30d=-10.46% | Revisions=-40% | GrowthEPS=-29.9% | GrowthRev=+10.2%
EPS next Year (2027-12-31): EPS=0.72 | Chg30d=-6.89% | Revisions=-40% | GrowthEPS=+63.0% | GrowthRev=+11.0%
[Analyst] Revisions Ratio: -73% (up=0, down=8)